Icagen.

PositionTRIANGLE

DURHAM -- Less than two years after its initial public offering of stock, Icagen is in danger of being delisted by Nasdaq. The drug developer's shares plummeted from about $4 to about $1 in early August after an unfavorable report on its first drug candidate, a treatment for sickle cell anemia...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT